Acceleris Capital client, BiVictriX Therapeutics’ successful AIM-IPO

BiVictriX Therapeutics (AIM: BVX), an emerging biotechnology company applying a novel approach to develop next-generation cancer therapies using insights derived from frontline clinical experience, has today announced that it will be listed on the AIM market of the London Stock Exchange, raising £7.5m million from its initial public offering (IPO).

BiVictriX’s pioneering ‘precision’ approach to cancer treatment has the potential to deliver a broad pipeline of proprietary, first-in-class Bi-Cygni® therapeutics to enable potentially higher dosing and more aggressive tumour eradication in patients, without causing harmful side effects. Through access to state-of-the-art techniques, BiVictriX has identified a diverse library of cancer-specific antigen fingerprints that can be used for the treatment of a wide range of cancer indications. BiVictriX’s lead candidate, BVX001, is designed to deliver a game-changing therapeutic approach to patients with Acute Myeloid Leukaemia (AML).

As a component of the IPO, Iain Ross will join the board as Chair, together with experienced non-executive directors Susan Lowther and Drummond Paris. Professor Bob Hawkins, a world-renowned oncologist and biotech innovator completes the Board and will add significant scientific support.

With BiVictriX’s listing on AIM, 33-year-old CEO Tiffany Thorn becomes one of the youngest female CEOs of a UK-based publicly listed technology firm.

Acceleris has acted as adviser to BiVictriX since start-up in 2016. Following the initial seed-round, Acceleris has successfully raised further capital to help BVX to progress its exciting drug development technology. BiVictriX has also been a typical showcase of Acceleris’s range of services which it can provide to the companies which it advises having provided the Chairman role, Accounting & Finance support, Company Secretarial as well as building the new website for the Company on top of traditional corporate finance and fundraising expertise.

CEO and Founder of BiVictriX, Tiffany Thorn, said: “This is an exciting step for all of us at BiVictriX. This fundraise will allow us to accelerate our growth and expedite the development and delivery of our next-generation, highly selective cancer therapeutics to patients diagnosed with some of the most difficult-to-treat cancers, in urgent need of more effective therapies. We would like to take this opportunity to offer our sincere gratitude and thanks to all of our supportive advisers and investors, both old and new, for their support in enabling us to carry out this crucial work.”

Outgoing Chairman, Norman Molyneux said: “We’ve worked with BiVictriX and Tiffany since start-up, providing a range of our services and it is always especially pleasing to see one of our clients make this leap onto AIM. We believe in being a long-term partner to the companies which we advise and this transaction is testament to that long-term support and vision. BiVictriX is developing a truly unique approach that will revolutionise treatment of hard-to-fight cancers like AML. The work BiVictriX does fits in with our company ethos and it has been a privilege to work with Tiffany over the years and we wish the Company future success in its life as a public company.” 

BiVictriX is the third drug development company that Acceleris Capital has supported to list on AIM in the last 6 years.

ENDS

For further information, please contact:

About BiVictriX Therapeutics

Derived from frontline clinical experience, BiVictriX is a rapidly emerging biotechnology company applying a novel approach to develop safer, more effective cancer therapies. The Company, which recently listed on the AIM of the London Stock Exchange (AIM: BVX), is pioneering a novel approach to cancer treatment based on its proprietary Bi-Cygni^® therapeutics, which enable potentially higher dosing and more aggressive tumour eradication without causing harmful side-effects to patients. BiVictriX’s access to state of the art techniques identify combinations of cancer-specific targets for both solid and liquid tumours. The Company’s lead candidate is BVX001, designed to bring a truly novel immunotherapeutic approach to patients with acute myeloid leukemia (AML).

BiVictriX is headquartered in Macclesfield, UK, with additional specialised laboratory facilities in St Asaph, Wales. For more information visit https://www.bivictrix.com/.

About Acceleris Capital

Acceleris Capital are an FCA regulated Investment Advisory house who focus on early-stage technology SMEs working on global unmet needs in healthcare, sustainability and software.

Since incorporation in 2000, Acceleris have advised and managed fundraisings for over 60 UK businesses and introduced over £150m investment, with a track record including start-up to IPO, trade sale and private equity exits.

Acceleris primarily source funding from their private angel group, Acceleris Ventures, global investment institutions and family office investors.